Company MedRx Co., Ltd

Company MedRx Co., Ltd

4586

JP3921220004

Pharmaceuticals

Equities

4586

JP3921220004

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-08 am EDT			5-day change	1st Jan Change
119 ^JPY	+4.39%		+2.59%	-21.19%

Feb. 05	MedRx Co., Ltd announced that it has received ¥1.9076 million in funding from Evolution Capital Management LLC	CI
Jan. 11	MedRx Co., Ltd announced that it expects to receive ¥1.9076 million in funding from Evolution Capital Management LLC	CI

Medrx Co., Ltd. is a Japan-based Company principally engaged in the research and development of pharmaceutical products. The Company produces new medicines based on percutaneous absorption formulation technology. The Company has pharmaceutical formulation technology, including percutaneous absorbent technology of ionic liquid transdermal system (ILTS) using characteristics of ionic liquid, and percutaneous absorbent technology of nano-sized colloid transdermal system (NCTS) using Nano colloidization technology of drug. Based on the technology, The Company aims to maximize drug efficacy, reduce side effects, prevent forgetting to drink, and to administer to patients who are difficult to orally administer, and to produce medicines with new added value.

Number of employees: 22

JPY in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical Formulation Development and Related Operations 100.0 %	59	100.0 %	30	100.0 %	-50.35%

JPY in Million	2022	Weight	2023	Weight	Delta
United States 75.6 %	-	-	22	75.6 %	-
Japan 24.4 %	59	100.0 %	7	24.4 %	-87.87%

Managers	Title	Age	Since
Masayoshi Matsumura FOU	Founder	79	02-01-14
Yonehiro Matsumura PSD	President	53	03-07-31
Ken Fujioka ADM	Chief Administrative Officer	56	18-10-31
Hidetoshi Hamamoto CTO	Chief Tech/Sci/R&D Officer	55	02-01-14
Hiroshi Akitomo BRD	Director/Board Member	63	02-05-31
Keiko Yamasaki BRD	Director/Board Member	74	02-01-14
Masaru Fukui AUD	Comptroller/Controller/Auditor	75	08-08-31

Members of the board	Title	Age	Since
Masayoshi Matsumura FOU	Founder	79	02-01-14
Yonehiro Matsumura PSD	President	53	03-07-31
Keiko Yamasaki BRD	Director/Board Member	74	02-01-14
Hiroshi Akitomo BRD	Director/Board Member	63	02-05-31
Hidetoshi Hamamoto CTO	Chief Tech/Sci/R&D Officer	55	02-01-14
Kunio Iwatani BRD	Director/Board Member	82	16-02-29
Ken Fujioka ADM	Chief Administrative Officer	56	18-10-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	41,841,100	38,981,198 ( 93.16 %)	2 ( 0.000005 %)	93.16 %

Name	Equities	%	Valuation
Matsumura Family 1.404 %	540,300	1.404 %	496 228 ¥
Hiroshi Yamashita 0.7448 %	286,600	0.7448 %	263 222 ¥
Shuzo Kawabata 0.6504 %	250,300	0.6504 %	229 883 ¥
Yonehiro Matsumura 0.6058 %	233,100	0.6058 %	214 086 ¥
Masayoshi Matsumura 0.5197 %	200,000	0.5197 %	183 686 ¥

Medrx Co., Ltd.

431-7 Nishiyama

769-2712, Higashikagawa

http://www.medrx.co.jp

Company calendar

	1st Jan change	Capi.
MEDRX CO., LTD	-21.19%	30.23M
MERCK KGAA	+8.08%	71.94B
KYOWA KIRIN CO. LTD.	+11.16%	9.27B
SK BIOPHARMACEUTICALS CO., LTD.	-11.55%	5.13B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+48.05%	4.66B
YUHAN CORPORATION	+5.09%	3.97B
BETTA PHARMACEUTICALS CO., LTD.	-14.74%	2.55B
INDIVIOR PLC	+19.24%	2.41B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-24.89%	2.36B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+21.45%	2.21B

Specialty & Advanced Pharmaceuticals

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Specialty & Advanced Pharmaceuticals